Reason
Viking Therapeutics stock fell after Novo Nordisk reported positive phase 1 results for experimental obesity drug amycretin. Amycretin achieved similar weight loss as Viking's VK2735 did in a phase 2 study. However, Viking could still have a big opportunity with VK2735 and its promising experimental NASH drug.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Super Dave : but none of these companies will be able to keep up with demand.